PriceTargets.com logo

Mind Medicine (MindMed) - MNMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.38
  • Forecasted Upside: 292.80%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 3 Strong Buy Ratings
$6.46 As of 10/30/2024 03:58 PM ET
▲ +0.01 (0.16%)

This chart shows the closing price for MNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mind Medicine (MindMed) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNMD

Analyst Price Target is $25.38
▲ +292.80% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $25.38, with a high forecast of $55.00 and a low forecast of $9.00. The average price target represents a 292.80% upside from the last price of $6.46.

This chart shows the closing price for MNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Mind Medicine (MindMed). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 3 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/14/2024Leerink PartnersInitiated CoverageOutperform$20.00
10/11/2024Leerink PartnrsUpgradeStrong-Buy
9/16/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $14.00
8/29/2024HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $55.00
7/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
7/24/2024Roth CapitalUpgradeStrong-Buy
7/24/2024Roth MkmInitiated CoverageBuy ➝ Buy$36.00 ➝ $36.00
6/21/2024Cantor FitzgeraldReiterated RatingOverweight
6/5/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$22.00 ➝ $22.00
5/29/2024Baird R WUpgradeStrong-Buy
5/28/2024Robert W. BairdInitiated CoverageOutperform$27.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$29.00 ➝ $20.00
5/10/2024HC WainwrightLower TargetBuy ➝ Buy$75.00 ➝ $35.00
4/15/2024Leerink PartnrsReiterated RatingOutperform
4/15/2024Leerink PartnersInitiated CoverageOutperform$20.00
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$14.00 ➝ $15.00
12/5/2023Canaccord Genuity GroupInitiated CoverageBuy$9.00
10/23/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
8/4/2023HC WainwrightReiterated RatingBuy$75.00
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$5.00 ➝ $7.00
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00
4/14/2023OppenheimerReiterated RatingOutperform$22.00
3/16/2023HC WainwrightReiterated RatingBuy$75.00
3/10/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00
3/10/2023Royal Bank of CanadaReiterated RatingOutperform$5.00
1/19/2023HC WainwrightReiterated RatingBuy$75.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$21.00
12/15/2022UBS GroupInitiated CoverageBuy$21.00
12/9/2022Roth CapitalReiterated RatingBuy$25.00
11/21/2022Canaccord Genuity GroupLower Target$22.00 ➝ $18.00
11/16/2022Royal Bank of CanadaInitiated CoverageOutperform
11/14/2022Maxim GroupLower Target$22.50 ➝ $8.00
10/4/2022Canaccord Genuity GroupLower TargetBuy$60.00 ➝ $22.00
9/21/2022HC WainwrightBoost TargetBuy$75.00
8/30/2022OppenheimerBoost Target$3.50 ➝ $52.00
8/25/2022OppenheimerInitiated CoverageOutperform
8/16/2022HC WainwrightLower TargetBuy$150.00 ➝ $75.00
8/10/2022Cantor FitzgeraldInitiated CoverageOverweight$45.00
5/23/2022HC WainwrightReiterated RatingBuy$150.00
5/4/2022Roth CapitalInitiated CoverageBuy$105.00
8/5/2021HC WainwrightInitiated CoverageBuy$150.00
6/28/2021Maxim GroupInitiated CoverageBuy$90.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Mind Medicine (MindMed) logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $6.46
Low: $6.36
High: $6.63

50 Day Range

MA: $5.99
Low: $5.17
High: $6.65

52 Week Range

Now: $6.46
Low: $2.41
High: $12.22

Volume

257,190 shs

Average Volume

1,399,012 shs

Market Capitalization

$466.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Mind Medicine (MindMed)?

The following Wall Street research analysts have issued stock ratings on Mind Medicine (MindMed) in the last year: Baird R W, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., Robert W. Baird, Roth Capital, Roth Mkm, and Royal Bank of Canada.
View the latest analyst ratings for MNMD.

What is the current price target for Mind Medicine (MindMed)?

8 Wall Street analysts have set twelve-month price targets for Mind Medicine (MindMed) in the last year. Their average twelve-month price target is $25.38, suggesting a possible upside of 293.4%. HC Wainwright has the highest price target set, predicting MNMD will reach $55.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $9.00 for Mind Medicine (MindMed) in the next year.
View the latest price targets for MNMD.

What is the current consensus analyst rating for Mind Medicine (MindMed)?

Mind Medicine (MindMed) currently has 9 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNMD will outperform the market and that investors should add to their positions of Mind Medicine (MindMed).
View the latest ratings for MNMD.

What other companies compete with Mind Medicine (MindMed)?

Other companies that are similar to Mind Medicine (MindMed) include Tilray, Cronos Group, USANA Health Sciences, Canopy Growth and Aurora Cannabis. Learn More about companies similar to Mind Medicine (MindMed).

How do I contact Mind Medicine (MindMed)'s investor relations team?

The company's listed phone number is 650-208-2454 and its investor relations email address is [email protected]. The official website for Mind Medicine (MindMed) is www.mindmed.co. Learn More about contacing Mind Medicine (MindMed) investor relations.